Revvity
Revvity, Inc. (NYSE: RVTY) provides health science technologies, products, software, expertise and services spanning life sciences research and clinical diagnostics. Its Life Sciences segment supplies reagents, instruments, laboratory automation, software and technology to pharmaceutical and biotechnology companies,… From the company’s description.
In fiscal 2025, Revvity reported revenue of $2.86B, up 3.7% from fiscal 2024, and net income of $239.88M. Its operating margin was 12.5%, and operations generated $582.93M in cash. Over the twelve months to Jul 5, 2026, revenue was $2.91B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Revvity does
In the company’s own words
Revvity, Inc. (NYSE: RVTY) provides health science technologies, products, software, expertise and services spanning life sciences research and clinical diagnostics. Its Life Sciences segment supplies reagents, instruments, laboratory automation, software and technology to pharmaceutical and biotechnology companies, contract research organizations, academic and government institutions, and other researchers. Its Diagnostics segment provides instruments, reagents, assays and software for hospitals, medical laboratories, clinicians and research professionals, with a focus on reproductive health, immunodiagnostics and emerging-market diagnostics. Offerings include newborn and prenatal screening, genetic and infectious-disease testing, and laboratory informatics. Major brands include BioLegend, Signals, IVIS, DELFIA, EUROIMMUN, T-SPOT and Vanadis. Revvity markets in more than 160 countries and employed approximately 11,000 people as of December 28, 2025; its sales and service network included about 2,000 representatives in approximately 40 countries. Its website is http://www.revvity.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 31791
- SIC
- 3826
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Revvity — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Revvity’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Revvity’s bonds, as funds hold them
Funds report holding 5 issues of Revvity’s debt, $407.98M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.73%, maturing 2028 to 2051.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Revvity and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Revvity's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Revvity's last four quarterly filings that the numbers alone won't show?”